The SPIN Cohort is a group of people with scleroderma from around the world who participate in SPIN’s online studies. Cohort participants are recruited by rheumatologists and other scleroderma healthcare providers from over 40 clinical sites in 7 countries. Through the cohort, SPIN collects information about important challenges to people with scleroderma and their support needs. Some cohort participants are also invited to test SPIN’s online support programs for scleroderma before releasing them to the public.
Click here to learn more about the cohort: www.spinsclero.com/cohort
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
To read the press release, click here.
For immediate release
Montreal, November 1st, 2016 – Scleroderma Quebec raised more than $ 240 000 during its benefit evening which was held at Montreal’s Cabaret du Casino on November 1st. The funds will be used to support patients who have scleroderma and to finance the research required to find a cure. The event was organized under the Honorary Presidency of Mr. François Armand, RBC Royal Bank’s Regional Vice-President of Commercial Financial Services, Quebec Branch. About 500 people attended the dinner-show starring Robert Charlebois who came back one more time this year by popular demand.
Nutrition and recipe book for people with scleroderma
It can be a challenge to know what to eat for the betterment of one’s health. This is particularly true for those affected by the numerous symptoms of scleroderma. (more…)
Do you have scleroderma? Are you interested in helping advance research on scleroderma support groups? If so, please lend a hand by completing this short 10-15 minute survey! (more…)
Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit® (macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH. (more…)